全球慢性心臟衰竭市场：按地区和国家分析和预测（2025 年至 2035 年）

Chronic Heart Failure Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035

出版日期: 2025年06月30日 | 出版商:

BIS Research | 英文 100 Pages | 商品交期: 1-5个工作天内

价格

简介目录图表

慢性心臟衰竭市场的主要成长要素之一是心血管疾病盛行率的上升。

随着高血压、冠状动脉疾病、糖尿病和肥胖等心血管疾病变得越来越普遍，慢性心臟衰竭的发生率也在增加，对有效治疗方法的需求也增加。此外，人口老化也对市场扩张做出了重大贡献。由于老年人心臟衰竭的风险更高，人口老化也对市场扩张做出了重大贡献。诊断技术和治疗方法的进步也使得人们能够更早发现并更有效地管理慢性心臟衰竭，进一步推动了市场成长。 SGLT2抑制剂和植入式设备等创新新治疗方法和医疗设备设备的开发正在改善患者的预后，加速了对治疗的需求。随着越来越多的患者被诊断出患有心臟衰竭并且寿命延长，对更好的治疗和管理方法的需求也在不断扩大，从而推动了慢性心臟衰竭市场的成长。

儘管市场正在成长，但仍存在一些挑战，阻碍其发展。其中一个主要挑战是治疗费用高。包括新药研发、医疗设备和住院费用在内的先进治疗方法往往很昂贵，导致一些患者难以获得所需的治疗。尤其是在医疗基础设施薄弱的低收入国家和新兴市场，这些高成本治疗的可近性受到限制。

另一个重大挑战是治疗的复杂性。慢性心臟衰竭衰竭是一种多因素疾病，具有多种潜在病因，许多患者也患有糖尿病、高血压和肾臟疾病等併发症。这使得采用一刀切的治疗方法变得困难，需要结合药物和非药物疗法进行多层面的管理。此外，由于疾病是慢性的，患者往往难以坚持复杂的治疗方案，导致预后较差，再住院率较高。

此外，儘管新的药物疗法前景光明，但某些患者群体仍然缺乏有效的治疗方法。尤其是射血分数保留型心臟衰竭衰竭(HFpEF) 患者，治疗方法与射血分数降低型心臟衰竭(HFrEF) 患者相比有限，导致该领域存在大量未满足的医疗需求。

最后，慢性心臟衰竭早期诊断不足和延误诊断仍然是一项重大挑战。许多患者直到症状出现才意识到病情，而延迟诊断会导致预后不良和介入效果受限。儘管早期识别和管理慢性心臟衰竭至关重要，但在某些地区，由于缺乏认知和筛检系统，诊断常常被延误。

本报告调查了全球慢性心臟衰竭市场，并总结了主要趋势、影响市场的因素分析、法律制度、临床试验趋势、市场规模趋势和预测、各个细分市场、地区/主要国家的详细分析、竞争格局和主要企业的概况。

主要策略和发展
- M&A
- 协同活动
- 业务扩展和资金筹措
- 产品发布和核准
- 其他活动
公司简介
- AstraZeneca
- Bristol Myers Squibb
- Cytokinetics
- Bayer AG
- Eli Lilly and Company
- Novartis AG
- Pfizer Inc.
- Johnson & Johnson
- Amgen Inc.
- Takeda Pharmaceutical Company
- AbbVie Inc.
- Sanofi

第四章调查方法

简介目录图表

Product Code: BHL3066SA

Global Chronic Heart Failure Market, Analysis and Forecast: 2025-2035

Chronic heart failure is a long-term condition where the heart is unable to pump blood efficiently to meet the body's needs for oxygen and nutrients. This inability to pump effectively leads to fluid buildup in the lungs, abdomen, and legs, causing symptoms such as shortness of breath, fatigue, swelling, and exercise intolerance. chronic heart failure can develop because of underlying conditions such as coronary artery disease, hypertension, diabetes, or previous heart attacks. The condition can be classified into two main types based on heart function: Heart Failure with Reduced Ejection Fraction (HFrEF), where the heart's pumping ability is weakened, and Heart Failure with Preserved Ejection Fraction (HFpEF), where the heart muscle becomes stiff and doesn't fill properly. Chronic heart failure is progressive, meaning it worsens over time, and requires ongoing management with medications, lifestyle changes, and sometimes medical devices or surgeries to improve symptoms and quality of life.

One of the key drivers of the chronic heart failure market is the rising prevalence of cardiovascular diseases such as hypertension, coronary artery disease, diabetes, and obesity. As these conditions become more widespread, the incidence of chronic heart failure increases, driving demand for effective treatments. The aging population is also contributing significantly to the growing market, as older individuals are at higher risk for developing heart failure. Additionally, advancements in diagnostic technologies and treatment options are allowing for earlier detection and more effective management of chronic heart failure, further boosting the market. The development of new, innovative therapies and medical devices, such as SGLT2 inhibitors and implantable devices, is improving patient outcomes, which in turn is accelerating the demand for chronic heart failure treatments. As more individuals are diagnosed and live longer with heart failure, the need for better treatment and management options continues to expand, propelling chronic heart failure market growth.

Despite the growth of the chronic heart failure market, several challenges continue to hinder its progress. One of the primary challenges is the high cost of treatment. The development of advanced therapies, including new drug classes, medical devices, and hospitalization costs, can be prohibitively expensive, making it difficult for some patients to access the necessary care. This is especially true in low-income and emerging markets, where healthcare infrastructure may be limited.

Another significant challenge is the complexity of treatment. chronic heart failure is a multifactorial disease with various underlying causes, and patients often present with comorbidities such as diabetes, hypertension, and kidney disease. This makes it difficult to develop a one-size-fits-all treatment approach, and managing the disease often requires a combination of pharmacological and non-pharmacological interventions. Moreover, the long-term nature of the condition means that adherence to complex treatment regimens is often low, leading to poor outcomes and increased hospitalizations.

Additionally, while new drug therapies have shown promise, there is still a lack of effective treatments for certain subsets of patients, particularly those with heart failure with preserved ejection fraction (HFpEF). This group of patients has limited treatment options compared to those with heart failure with reduced ejection fraction (HFrEF), leaving a significant unmet need in the chronic heart failure market.

Finally, the underdiagnosis and delayed diagnosis of chronic heart failure in its early stages also poses a major challenge. Many patients may not experience noticeable symptoms until the disease is advanced, leading to poor prognosis and reduced effectiveness of interventions. Early identification and management of chronic heart failure are critical, but the lack of awareness and insufficient screening programs in some regions contribute to late-stage diagnoses.

These challenges underscore the need for continued innovation, improved accessibility, and early detection strategies to overcome the barriers to effective chronic heart failure management.

The global chronic heart failure market is highly competitive, with several key players driving innovation and market growth. Leading companies such as AstraZeneca, Bristol Myers Squibb, Cytokinetics, Bayer AG, Eli Lilly and Company, and scPharmaceuticals are at the forefront of the market, each contributing through innovative therapies, medical devices, and treatments. These companies are focusing on expanding the availability of advanced drug therapies such as SGLT2 inhibitors (e.g., dapagliflozin), neprilysin inhibitors (e.g., sacubitril/valsartan), and ARBs, all of which are transforming the treatment of heart failure. Additionally, advancements in medical devices for heart failure management, such as implantable defibrillators and ventricular assist devices, are contributing to better patient outcomes. As these companies continue to invest in research and development, the competition within the chronic heart failure market is driving further innovation, ultimately leading to more effective treatments, improved patient quality of life, and reduced hospitalizations.

Chronic Heart Failure Market Segmentation:

Chronic Heart Failure Segmentation 1: by Region

North America
Europe
Asia-Pacific

The global chronic heart failure market is experiencing significant transformation driven by several emerging trends. There is a growing emphasis on personalized medicine, with advancements in genomic testing and biomarker identification allowing for more tailored treatments that are specific to the patient's unique condition, improving the effectiveness of therapies. Additionally, innovative drug therapies such as SGLT2 inhibitors, neprilysin inhibitors, and ARBs are gaining prominence for their ability to not only improve heart function but also reduce hospitalizations and enhance survival rates, particularly in patients with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).

Another major trend is the increasing integration of digital health technologies such as wearables, remote monitoring devices, and telemedicine, which enable continuous tracking of patient health and more proactive management of chronic heart failure symptoms. These technologies help detect early signs of deterioration, prevent hospital readmissions, and optimize treatment regimens. Furthermore, the growing focus on patient-centred care is reshaping the chronic heart failure market by promoting a holistic approach to chronic heart failure management, combining pharmacological treatments with lifestyle modifications, rehabilitation, and psychological support to improve the quality of life for patients.

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Chronic Heart Failure Market: Industry Outlook

1.1 Introduction
1.2 Market Trends
1.3 Regulatory Framework
1.4 Epidemiology Analysis
1.5 Clinical Trial Analysis
1.6 Market Dynamics
- 1.6.1 Impact Analysis
- 1.6.2 Market Drivers
- 1.6.3 Market Challenges
- 1.6.4 Market Opportunities

2. Global Chronic Heart Failure Market (Region), ($Billion), 2023-2035

2.1 North America
- 2.1.1 Key Findings
- 2.1.2 Market Dynamics
- 2.1.3 Market Sizing and Forecast
  - 2.1.3.1 North America Chronic Heart Failure Market, by Country
    - 2.1.3.1.1 U.S.
2.2 Europe
- 2.2.1 Key Findings
- 2.2.2 Market Dynamics
- 2.2.3 Market Sizing and Forecast
  - 2.2.3.1 Europe Chronic Heart Failure Market, by Country
    - 2.2.3.1.1 Germany
    - 2.2.3.1.2 U.K.
    - 2.2.3.1.3 France
    - 2.2.3.1.4 Italy
2.3 Asia Pacific
- 2.3.1 Key Findings
- 2.3.2 Market Dynamics
- 2.3.3 Market Sizing and Forecast
  - 2.3.3.1 Asia Pacific Chronic Heart Failure Market, by Country
    - 2.3.3.1.1 China
    - 2.3.3.1.2 Japan

3. Global Chronic Heart Failure Market: Competitive Landscape and Company Profiles

3.1 Key Strategies and Development
- 3.1.1 Mergers and Acquisitions
- 3.1.2 Synergistic Activities
- 3.1.3 Business Expansions and Funding
- 3.1.4 Product Launches and Approvals
- 3.1.5 Other Activities
3.2 Company Profiles
- 3.2.1 AstraZeneca
  - 3.2.1.1 Overview
  - 3.2.1.2 Top Products / Product Portfolio
  - 3.2.1.3 Top Competitors
  - 3.2.1.4 Target Customers/End-Users
  - 3.2.1.5 Key Personnel
  - 3.2.1.6 Analyst View
- 3.2.2 Bristol Myers Squibb
  - 3.2.2.1 Overview
  - 3.2.2.2 Top Products / Product Portfolio
  - 3.2.2.3 Top Competitors
  - 3.2.2.4 Target Customers/End-Users
  - 3.2.2.5 Key Personnel
  - 3.2.2.6 Analyst View
- 3.2.3 Cytokinetics
  - 3.2.3.1 Overview
  - 3.2.3.2 Top Products / Product Portfolio
  - 3.2.3.3 Top Competitors
  - 3.2.3.4 Target Customers/End-Users
  - 3.2.3.5 Key Personnel
  - 3.2.3.6 Analyst View
- 3.2.4 Bayer AG
  - 3.2.4.1 Overview
  - 3.2.4.2 Top Products / Product Portfolio
  - 3.2.4.3 Top Competitors
  - 3.2.4.4 Target Customers/End-Users
  - 3.2.4.5 Key Personnel
  - 3.2.4.6 Analyst View
- 3.2.5 Eli Lilly and Company
  - 3.2.5.1 Overview
  - 3.2.5.2 Top Products / Product Portfolio
  - 3.2.5.3 Top Competitors
  - 3.2.5.4 Target Customers/End-Users
  - 3.2.5.5 Key Personnel
  - 3.2.5.6 Analyst View
- 3.2.6 Novartis AG
  - 3.2.6.1 Overview
  - 3.2.6.2 Top Products / Product Portfolio
  - 3.2.6.3 Top Competitors
  - 3.2.6.4 Target Customers/End-Users
  - 3.2.6.5 Key Personnel
- 3.2.7 Pfizer Inc.
  - 3.2.7.1 Overview
  - 3.2.7.2 Top Products / Product Portfolio
  - 3.2.7.3 Top Competitors
  - 3.2.7.4 Target Customers/End-Users
  - 3.2.7.5 Key Personnel
  - 3.2.7.6 Analyst View
- 3.2.8 Johnson & Johnson
  - 3.2.8.1 Overview
  - 3.2.8.2 Top Products / Product Portfolio
  - 3.2.8.3 Top Competitors
  - 3.2.8.4 Target Customers/End-Users
  - 3.2.8.5 Key Personnel
  - 3.2.8.6 Analyst View
- 3.2.9 Amgen Inc.
  - 3.2.9.1 Overview
  - 3.2.9.2 Top Products / Product Portfolio
  - 3.2.9.3 Top Competitors
  - 3.2.9.4 Target Customers/End-Users
  - 3.2.9.5 Key Personnel
  - 3.2.9.6 Analyst View
- 3.2.10 Takeda Pharmaceutical Company
  - 3.2.10.1 Overview
  - 3.2.10.2 Top Products / Product Portfolio
  - 3.2.10.3 Top Competitors
  - 3.2.10.4 Target Customers/End-Users
  - 3.2.10.5 Key Personnel
  - 3.2.10.6 Analyst View
- 3.2.11 AbbVie Inc.
  - 3.2.11.1 Overview
  - 3.2.11.2 Top Products / Product Portfolio
  - 3.2.11.3 Top Competitors
  - 3.2.11.4 Target Customers/End-Users
  - 3.2.11.5 Key Personnel
  - 3.2.11.6 Analyst View
- 3.2.12 Sanofi
  - 3.2.12.1 Overview
  - 3.2.12.2 Top Products / Product Portfolio
  - 3.2.12.3 Top Competitors
  - 3.2.12.4 Target Customers/End-Users
  - 3.2.12.5 Key Personnel
  - 3.2.12.6 Analyst View